Clinical Characteristics, Guideline-Directed Medical Therapy, and Factors Associated With Prior Heart Failure Hospitalization in a Tertiary Bahraini Cohort: A Retrospective Observational Study
Journal of the Saudi Heart Association · 19.11.2026 · 38 (4)
DOI: 10.37616/2212-5043.1539 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of the Saudi Heart Association, online erschienen am 19.11.2026. Verfasst von Adel Khalifa Hamad und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Objectives
Guideline-directed medical therapy (GDMT) reduces morbidity and mortality in heart failure with reduced ejection fraction, yet real-world uptake of all four foundational pillars remains incomplete, and contemporary Gulf data are limited. We characterized heart failure phenotypes, etiologies, GDMT uptake, iron-status assessment, and factors associated with recent hospitalization in a tertiary cohort in Bahrain.
Methods
We conducted a retrospective observational study of 250 consecutive adult heart failure outpatients managed at a national tertiary cardiac center between January and June 2024. Patients were stratified by left ventricular ejection fraction (LVEF) into reduced (≤40%), mildly reduced (41–49%), and preserved (≥50%) phenotypes. We assessed GDMT across four pillars: renin–angiotensin system (RAS) inhibition, beta-blockade, mineralocorticoid receptor antagonism, and sodium–glucose cotransporter 2 (SGLT2) inhibition. Multivariable logistic regression identified factors associated with at least one heart failure hospitalization during the previous 12 months. Guideline-defined iron deficiency was assessed in patients with complete iron studies.
Results
Mean age was 60.7 years, 68.4% were male, and reduced ejection fraction predominated (84.4%). RAS inhibitor and beta-blocker use were high (92.9% and 94.8%), whereas mineralocorticoid receptor antagonist (MRA) (73.5%) and SGLT2 inhibitor (59.7%) use were lower; 78.7% received at least three pillars, and 47.4% received all four. Iron deficiency was present in 83 of 124 assessable patients (66.9%). Prior hospitalization had occurred in 82 patients (32.8%). In multivariable analysis, hypertension and New York Heart Association (NYHA) class II–IV were associated with higher odds of prior hospitalization, whereas higher hemoglobin was associated with lower odds.
Conclusions
In this contemporary Bahraini cohort, foundational therapy uptake was high, though SGLT2 inhibitors represented the largest four-pillar gap, and fewer than half received all four pillars. Guideline-defined iron deficiency was highly prevalent among assessable patients. Hypertension, greater symptomatic limitation, and lower hemoglobin were independently associated with prior hospitalization.
Zitieren
APA
Hamad, A. K., Alhashli, A. J., Masood, A. S., Yusuf, K. A., Saif, H. S., & Hazeem, L. M. (2026). Clinical Characteristics, Guideline-Directed Medical Therapy, and Factors Associated With Prior Heart Failure Hospitalization in a Tertiary Bahraini Cohort: A Retrospective Observational Study. Journal of the Saudi Heart Association, 38(4). https://doi.org/10.37616/2212-5043.1539
Vancouver
Hamad AK, Alhashli AJ, Masood AS, Yusuf KA, Saif HS, Hazeem LM. Clinical Characteristics, Guideline-Directed Medical Therapy, and Factors Associated With Prior Heart Failure Hospitalization in a Tertiary Bahraini Cohort: A Retrospective Observational Study. Journal of the Saudi Heart Association. 2026;38(4). doi:10.37616/2212-5043.1539
BibTeX
@article{Hamad2026,
author = {Hamad, Adel Khalifa and Alhashli, Ali Jassim and Masood, Abdulrahman Saad and Yusuf, Khalifa Abdulrahman and Saif, Hamad Salman and Hazeem, Latifa Mohamed},
title = {Clinical Characteristics, Guideline-Directed Medical Therapy, and Factors Associated With Prior Heart Failure Hospitalization in a Tertiary Bahraini Cohort: A Retrospective Observational Study},
journal = {Journal of the Saudi Heart Association},
year = {2026},
volume = {38},
number = {4},
doi = {10.37616/2212-5043.1539}
}
EUVIMED